A recent study conducted by researchers from Seattle-based University of Washington and Durham, N.C.-based Duke University found a strong association between the use of fall-risk increasing drugs and ...

Yum! Brands appointed Scott Mezvinsky as the new chief executive of Kentucky Fried Chicken, following the exit of current CEO Sabir Sami. Sami, who has been CEO of KFC since 2022, will exit his ...

and herbs (your doctor or pharmacist can help you fill out a medication list) what to do if you start taking a new drug during your Lexapro treatment It’s also important to understand Lexapro ...

Authentic owns more than 50 global brands that generate about $32 billion in annual retail sales. The company operates in 150 countries and says it has more than 13,000 freestanding stores and ...

(RTTNews) - Yum! Brands, Inc. (YUM) Monday, has announced that Scott Mezvinsky, will step into the role of KFC Division Chief Executive Officer. The promotion, effective March 1, will see ...

(RTTNews) - a.k.a. Brands Holding Corp. (AKA), a portfolio of next generation fashion brands, Monday announced that its preliminary fourth-quarter net sales increased 6.8% to around $159.0 million ...

SAN FRANCISCO, January 13, 2025--(BUSINESS WIRE)--a.k.a. Brands Holding Corp. (NYSE: AKA), a portfolio of next generation fashion brands, today announced that Ciaran Long has been appointed Chief ...

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.

Medicare plans have a list of medications, both brand-name and generic, they cover. This list is called a formulary. You can use it when comparing plans. Share on Pinterest alvarez/Getty Images ...

A new study suggests COPD patients experience improved lung ... as both can be fearful of losing control of the disease in a change of medication. The CRYSTAL trial is the first large-scale ...

Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment. Additionally, Regeneron and Sanofi have a second COPD candidate in IL-33 inhibitor itepekimab ...